Inflammatory bowel disease should be suspected in children or adults with the following symptoms (1) (2):
Please see CKS guidelines for :
Crohn's disease (1)
Please also see the Faecal Calprotectin page for advice on indications and interpretation of this test.
*Local gastroenterologists do not recommend routinely undertaking a faecal calprotectin in patients with non-specific symptoms alone.
Children (aged under 16)
For suspected IBD in children please see the Chronic abdominal pain and IBD (children) page.
Patients with suspected IBD should be referred urgently for a diagnosis. Please see 'What to do before referral' section below for further advice on investigations that need to be carried out in primary care before referral.
Suspected Malignancy
Patients with suspected lower GI cancer please use the 2WW pathway (Direct to test, if appropriate, or 2WW eReferral) or do a FIT test if indicated.
Acute Severe Colitis
Patients with acute severe colitis may need more immediate treatment or admission so please discuss with either the local medical on-call team, IBD specialist nurse/consultant if there’s a known diagnosis, or via A&G if the patient is not known to the unit.
Definition:
Please ensure patient does not meet criteria for 2WW referral - particularly if there is rectal bleeding. Also consider a FIT test if this is indicated and if positive then refer via 2WW.
If acute severe colitis is suspected then discuss with local gastroentrology team as immediate treatment or admission may be required - please see red flag section above.
Patients with suspected inflammatory bowel disease where the above red flags have been excluded should initially have investigations in primary care including:
If investigations including faecal calprotectin are normal, then please consider other diagnoses (see Irritable Bowel Syndrome page)
If symptoms have settled at 6 weeks following a previously high FCP , then repeat faecal calprotectin ensuring patient is not on PPI or NSAID.
If faecal calprotectin is falling or less then 250 mcg/g then consider watch and wait in primary care with safety netting and review again if symptoms recur.
If FCP is still raised (>250 mcg/g) then consider requesting gastroenterology advice and guidance.
If symptoms persist and above investigations still suggest IBD, then refer urgently to gastroenterology via eRS (please specify which hospital is preferred as there are different referral processes for each hospital). Alternatively, a referral for a direct access lower GI endoscopy may be appropriate for some patients with milder symptoms - see Referral Section below.
If patient has had a recent normal colonoscopy (direct access or otherwise) but faecal calprotectin is persistently raised (>250 mcg/g) and symptoms persist then refer to IBD clinic via eRS (to exclude small bowel disease).
Referral or advice options for patients with suspected IBD
If referral in indicated, the most appropriate referral route will depend on the patient's symptoms and outcome of initial investigations in primary care as well as where the patient lives and their preference of provider. Patients who have more severe or acute symptoms or are more likely to have IBD should be referred to secondary care. Other options may be appropriate if the symptoms are mild or less likely to be due to IBD. Patient choice via eRS ais limited due to the different referral criteria and pathways available:
The Inflammatory Bowel Disease Toolkit has been launched by Crohn’s & Colitis UK in partnership between the Royal College of General Practitioners (RCGP). It is designed to be to be a 'one-stop-shop', a user-friendly guide to IBD for GPs and other primary care professionals
The Crohn's and Colitis UK website also has information for patients and professionals.
The British Society of Gastroenterology Clinical Resources page has useful guidelines on management of a range of GI conditions including IBD.
Efforts are made to ensure the accuracy and agreement of these guidelines, including any content uploaded, referred to or linked to from the system. However, BNSSG ICB cannot guarantee this. This guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer, in accordance with the mental capacity act, and informed by the summary of product characteristics of any drugs they are considering. Practitioners are required to perform their duties in accordance with the law and their regulators and nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.
Information provided through Remedy is continually updated so please be aware any printed copies may quickly become out of date.